Registry tracking use of the CytoSorb blood-filter device in critically ill patients
Records real-world use of the CytoSorb device in critically ill people with serious conditions.
Key facts
- Who runs it
- CytoSorbents, Inc
- Where
- Krakow and Wroclaw, PolandSee the 2 sitesAlso in 5 other countries, 26 sites
- Trial code
- Registry title
- CytOSorb TreatMent Of Critically Ill PatientS Registry
- Status
- Recruiting
- People taking part
- 3,000 people, planned
- Started
- 22 Jun 2022
- Expected to end
- Sept 2032
- Type of study
- Observational
- Treatments tested
- CytoSorb
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The registry is looking for critically ill patients who are planned to receive, or already receive, the CytoSorb 300 mL device, and who give informed consent.
- Sex
- All sexes can join.
- Disease stage
- Critically ill patients, for example with septic shock, ARDS, trauma, rhabdomyolysis, cardiogenic shock, pancreatitis, liver failure, burns or CAR-T cytokine release syndrome.
- Earlier treatment
- The CytoSorb 300 mL device must be planned or already in use.
Main reasons for not taking part
- CytoSorb 300 mL used only to remove antithrombotic drugs
- CytoSorb 300 mL used only during cardiac surgery
- A complication or medical reason after consent that makes CytoSorb 300 mL no longer appropriate
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Planned OR actual CytoSorb® 300 mL device utilization
- Informed consent for prospective registry participation
Who cannot take part
- The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate
- Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
- Use of the CytoSorb® 300 mL device for antithrombotic removal only
Where in Poland
Also in 5 other countries, 26 sites
- SP ZOZ Szpital Uniwersytecki w KrakowieKrakow, PolandContact: Anna Wrzosek, Dr. (principal investigator)Taking people
- Uniwersyteckim Spitalem Klinicznym im. Jana Mikulicza - Radeckiego we WrocławiuWroclaw, PolandContact: Waldemar Goździk, Prof (principal investigator)Taking people
About the trial
What the trial wants to find out
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care
Treatments tested
- CytoSorb
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting
- Plain-language title
- Registry tracking use of the CytoSorb blood-filter device in critically ill patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 October 2026